Incidence, risk factors, and reasons for hospitalization among glioblastoma patients receiving chemoradiation

Despite a high symptom burden, little is known about the incidence or predictors of hospitalization among glioblastoma patients, including risks during chemoradiation (CRT). We studied 196 consecutive newly diagnosed glioblastoma patients treated at our institution from 2006-2010. Toxicity data were...

Full description

Saved in:
Bibliographic Details
Published in:Journal of neuro-oncology 2015-08, Vol.124 (1), p.137-146
Main Authors: Rahman, Rifaquat, Catalano, Paul J., Reardon, David A., Norden, Andrew D., Wen, Patrick Y., Lee, Eudocia Q., Nayak, Lakshmi, Beroukhim, Rameen, Dunn, Ian F., Golby, Alexandra J., Johnson, Mark D., Chiocca, E. Antonio, Claus, Elizabeth B., Alexander, Brian M., Arvold, Nils D.
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Brain Neoplasms - complications
Brain Neoplasms - therapy
Chemoradiotherapy
Clinical Study
Female
Glioblastoma - complications
Glioblastoma - therapy
Hospitalization - statistics & numerical data
Humans
Incidence
Male
Medicine
Medicine & Public Health
Middle Aged
Neurology
Oncology
Risk Factors
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Despite a high symptom burden, little is known about the incidence or predictors of hospitalization among glioblastoma patients, including risks during chemoradiation (CRT). We studied 196 consecutive newly diagnosed glioblastoma patients treated at our institution from 2006-2010. Toxicity data were reviewed during and after the CRT phase, defined as the period between diagnosis and 6 weeks after radiotherapy completion. Logistic regression and proportional hazards modeling identified predictors of hospitalization and overall survival (OS). Median age was 59 years (range, 23-90) and 83 % had Karnofsky performance status (KPS) score ≥ 70. Twenty-six percent of patients underwent gross total resection, 77 % received ≥ 59.4 Gy of radiotherapy, and 89 % received concurrent temozolomide. Median OS was 15.6 months (IQR, 8.5-26.8 months). Forty-three percent of patients were hospitalized during the CRT phase; OS was 10.7 vs. 17.8 months for patients who were vs. were not hospitalized, respectively ( P  
ISSN:0167-594X
1573-7373
DOI:10.1007/s11060-015-1820-3